Trau Group

Nanoscience, Nanotechnology, Molecular diagnostics

The Trau Group, led by ARC Australian Laureate Fellow Professor Matt Trau, brings together physical chemistry, biology, mathematics, bioengineering and nanoscience in a highly multi-disciplinary way to create new technologies that provide entirely new scientific insights and breakthroughs. 

One key focus area of the lab is to develop innovative nano-diagnostics and nano-manufactured medicines to help transform the healthcare system towards early detection and personalized treatment of disease. This approach aims to dramatically extend high quality human life through a combination of innovative diagnostic technology, on-demand molecular-guided therapies and preventative measures (The ultimate goal of Precision Medicine).  

Professor Trau has a joint appointment with SCMB.

Research Areas

  • Nanoscience 
  • Nanotechnology
  • Molecular diagnostics
  • Personalised medicine 

Research Approach

Our research focus is on developing diagnostic devices for early detection of diseases such as cancer, when it is most responsive to treatment which also provides the greatest social and economic benefits to society. Nanotechnology offers the promise of miniaturised, inexpensive, flexible and robust “plug-and-play” molecular reading systems which can be effectively deployed to detect diseases in a clinical setting.


An End to Cancer Mortality with Nano-Diagnostics | Matt Trau | TEDxUQ

Research with the Trau Group

The New Science of Ageing & Wellness - Dr Leroy Hood, Ravinder Sajwan & Matt Trau

Personalised Treatment for Breast Cancer, presented by Professor Matt Trau

It's a Small World - documentary on Nanotechnology & it's benefits to cancer research

Professor Matt Trau, NBCF funded researcher talks about his diagnostic research

On Liberty Ep.10 Matt Trau: Lessons to prevent the next pandemic


Since 2019

  • Motor Nuerone Disease (MND) (2024) A blood-based nanotechnology to decipher the extracellular vesicle code in ALS 
  • ARC Australian Laureate Fellowships (2024) Digital chemistry and catalysis: redefining reactions in confined systems
  • University of Sydney (2023) Rhythm and blues: Personalising care for body clock dysfunction in mood disorders (NHMRC Synergy)
  • University of Sydney (2023) Utilizing neurobiological markers of circadian-linked depression to improve responses to clinical care. (Wellcome Trust)
  • University of Newcastle (2022) The Development and Clinical Translation of Blood-Based Diagnostics for Brain Cancer (Mark Hughes Foundation administered by the University of Newcastle)
  • ARC Discovery Projects (2022) An integrated nano-bioengineered chip for enhanced molecular evolution
  • University of New South Wales (2022) Novel epigenetic blood test for breast cancer detection and monitoring (National Breast Cancer Foundation Grant administered by UNSW)
  • Cancer Australia (2022) nanoIMPAC: Monitoring immune toxicities and tumour immune evasion in lung cancer
  • University of Newcastle (2022) Can the brain's immune cell be used to track treatment response in high-grade glioma? (University of Newcastle led Mark Huges Foundation Brain Cancer Innovation Project Grant)
  • CannaPacific Pty Ltd (2021) Cannabis genetic marker development for the breeding of medicinal cannabis varieties
  • CSIRO (2021) The amplification of DNA from environmental metazoan cells (enCells)
  • Evolution Mining Limited (2021) Immunostorm Chip Research
  • ARC Discovery Projects (2021) Single molecule sensing on nanopillars: Reading complex molecular circuits
  • NHMRC Investigator Grants (2020) A protein phosphorylation mapping tool for monitoring tyrosine kinase inhibition therapy in cancer patients
  • ARC Discovery Early Career Researcher Award (2020) Harnessing nanotechnology to unravel extracellular vesicle heterogeneity
  • CSIRO Synthetic Biology Fellowship (2019) Engineering therapeutic cells for pan-cancer diagnosis and eradication
  • UQ-CSIRO collaboration agreement (2019) Precision Nanomedicine


Click here to view Trau group publications